| Reeds Pharmacy | |
| 71 Cowardly Lion Dr, Ste A, Hedgesville, West Virginia 25427 | |
| (304) 754-5800 |
| Name | Reeds Pharmacy |
|---|---|
| Organization Name | Rphv Llc |
| Location | 71 Cowardly Lion Dr, Ste A, Hedgesville, West Virginia 25427 |
| Type | Pharmacy |
| Phone | (304) 754-5800 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Neuralstem, Inc. announced that the first ALS patient was treated with its spinal cord stem cells yesterday at the Emory ALS Center at Emory University, in Atlanta, GA. A total of up to 18 patients is planned to be treated in this first U.S. clinical trial to evaluate human neural stem cells for the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease). ALS affects roughly 30,000 people in the U.S., with about 5,600 new diagnoses per year, according to the ALS Association.
The challenges related to assessing the safety of botanicals in foods and food supplements and regulating their use were highlighted at a conference held in Denmark in November 2014.
Today's headlines include a variety of reports about the health law's implementation as well as related developments from Capitol Hill.
A somatic mutation in the ATRX gene has recently been shown as a potential molecular marker for aggressive brain tumors, such as gliomas, neuroblastomas and pancreatic neuroendocrine tumors. Now, for the first time, researchers at Penn's Abramson Cancer Center have found that the same mutated gene may serve as a much-needed biomarker for the pheochromocytomas and paragangliomas (PCC/PGL) that become malignant.
› Verified 7 days ago
| NPI Number | 1083780191 |
| Organization Name | RPHV LLC |
| Doing Business As | RPHV LLC |
| Type | Pharmacy |
| Address | 71 Cowardly Lion Dr, Hedgesville, WV 25427 |
| Phone Number | 304-754-5800 |
News Archive
Neuralstem, Inc. announced that the first ALS patient was treated with its spinal cord stem cells yesterday at the Emory ALS Center at Emory University, in Atlanta, GA. A total of up to 18 patients is planned to be treated in this first U.S. clinical trial to evaluate human neural stem cells for the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease). ALS affects roughly 30,000 people in the U.S., with about 5,600 new diagnoses per year, according to the ALS Association.
The challenges related to assessing the safety of botanicals in foods and food supplements and regulating their use were highlighted at a conference held in Denmark in November 2014.
Today's headlines include a variety of reports about the health law's implementation as well as related developments from Capitol Hill.
A somatic mutation in the ATRX gene has recently been shown as a potential molecular marker for aggressive brain tumors, such as gliomas, neuroblastomas and pancreatic neuroendocrine tumors. Now, for the first time, researchers at Penn's Abramson Cancer Center have found that the same mutated gene may serve as a much-needed biomarker for the pheochromocytomas and paragangliomas (PCC/PGL) that become malignant.
› Verified 7 days ago
News Archive
Neuralstem, Inc. announced that the first ALS patient was treated with its spinal cord stem cells yesterday at the Emory ALS Center at Emory University, in Atlanta, GA. A total of up to 18 patients is planned to be treated in this first U.S. clinical trial to evaluate human neural stem cells for the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease). ALS affects roughly 30,000 people in the U.S., with about 5,600 new diagnoses per year, according to the ALS Association.
The challenges related to assessing the safety of botanicals in foods and food supplements and regulating their use were highlighted at a conference held in Denmark in November 2014.
Today's headlines include a variety of reports about the health law's implementation as well as related developments from Capitol Hill.
A somatic mutation in the ATRX gene has recently been shown as a potential molecular marker for aggressive brain tumors, such as gliomas, neuroblastomas and pancreatic neuroendocrine tumors. Now, for the first time, researchers at Penn's Abramson Cancer Center have found that the same mutated gene may serve as a much-needed biomarker for the pheochromocytomas and paragangliomas (PCC/PGL) that become malignant.
› Verified 7 days ago
Reeds Pharmacy Type: Pharmacy Location: 71 Cowardly Lion Dr, Hedgesville, West Virginia 25427 Phone: (304) 754-5800 |